Healthcare and Medical
Healthcare and Medical
home | healthcare and medical | company profile
Premium Company Profile - Idenix Pharmaceuticals, Inc. (Datamonitor)
- Market: Healthcare and Medical
- Published Date: 31/10/2007
- Report Title: Premium Company Profile - Idenix Pharmaceuticals, Inc.
- Table of Contents: View Table of Contents
- Report Type: Company Profile
- Country: Global
- Number of Pages: 43
Introduction
Idenix Pharmaceuticals develops drugs for the treatment of human viral and other infectious diseases. Novartis is the major shareholder of the company owning 56% of Idenix and has development and worldwide marketing rights for Idenix's HBV and HCV franchise.
Scope
Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
Idenix currently focuses on the development and commercialization of drugs for the treatment of hepatitis C and human immuno viral infections. The company's only approved product, Tyzeka/Sebivo for the hepatitis B virus, is developed, manufactured and marketed by Novartis and Idenix receives royalties on the product sales
The company's total revenues increased at a CAGR of 110% from $3 million to $67 million during 2002-2006, representing an absolute growth of +$64 million. As the company launched approved product Tyzeka in October 2006, it recorded $0.6 million of revenues from product sales in fiscal 2006
Idenix's revenues are forecast to increase from $67 million in 2006 to $198 million in 2010, growing at a CAGR of 31%. This represents an absolute growth of +$131 million during the period. Collaboration and license revenues from Novartis are expected to be the largest contributor to the company's overall revenue growth
Reasons to Purchase
Access all the important information and analysis on the company in a single report Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company's adjusted five year financial data along with key ratios and market capitalization
Scope
Highlights
Reasons to Purchase
Purchase Information
There are various ways to purchase products from our site. Select the report title(s) you are interested in, and add it to your basket. At the Checkout page, you will be requested to submit your details. You will then have the option to pay via various methods: Debit Card ; Credit Card ; Purchase via Invoice (inc. Purchase Order no. if required) and Paypal. Companiesandmarkets.com accepts Visa, MasterCard, Diners, American Express, JCB and all the major credit cards. Companiesandmarkets.com uses RBSWorldpay.
Once you have purchased your report(s), you will receive a confirmation email. You will then either be able to download your report(s) immediately from your Customer Area in PDF format, or the report(s) will be emailed to you directly, depending on the agreement we have with the publisher. Orders that are deliverable via email which are taken outside of working hours will be delivered next business day.
Please note, if you purchase by invoice, you will receive your report(s) once payment has been received. If you have any questions about how to order, please Contact Us.
